Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $22.0 million.

  • Gyre Therapeutics' Total Liabilities fell 1792.2% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 1792.2%. This contributed to the annual value of $27.0 million for FY2024, which is 2905.82% down from last year.
  • Gyre Therapeutics' Total Liabilities amounted to $22.0 million in Q3 2025, which was down 1792.2% from $23.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Total Liabilities ranged from a high of $38.1 million in Q4 2023 and a low of $1.6 million during Q3 2022
  • Moreover, its 5-year median value for Total Liabilities was $16.6 million (2021), whereas its average is $18.1 million.
  • In the last 5 years, Gyre Therapeutics' Total Liabilities plummeted by 9076.46% in 2022 and then skyrocketed by 31516.98% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Total Liabilities stood at $14.6 million in 2021, then dropped by 13.98% to $12.5 million in 2022, then soared by 203.65% to $38.1 million in 2023, then dropped by 29.06% to $27.0 million in 2024, then decreased by 18.65% to $22.0 million in 2025.
  • Its last three reported values are $22.0 million in Q3 2025, $23.2 million for Q2 2025, and $25.5 million during Q1 2025.